BioCentury
ARTICLE | Clinical News

Cytokinetics starts Phase Ib trial of CK-2127107 to treat eldery adults with limited mobility

July 21, 2017 6:48 PM UTC

Cytokinetics Inc. (NASDAQ:CYTK) and Astellas Pharma Inc. (Tokyo:4503) began a Phase 1b trial of CK-2127107 to treat elderly patients with limited mobility. The double-blind, crossover trial will enroll at least 60 patients to receive placebo or 500 mg CK-2127107 once daily on days 1 and 14 and twice daily on days 2-13. After a 14-day washout period, patients will then crossover to receive 14 days of the other treatment.

The trial’s primary endpoint is the change from baseline to day 14 in sum of peak torque during isokinetic knee extensions. Secondary endpoints include the short physical performance battery score, stair-climb test and 6-minute walk test (6MWT)...